The Foundation is governed by a board of directors that currently includes members from academia, consumer groups, the medical product and food industries, health care providers, and others. The FDA Commissioner and the Director of the National Institutes of Health serve as non-voting members of the Board. The statute prohibits government control of the foundation, and gives the Foundation no role in FDA’s regulatory process. Our bylaws outline the conflict of interest policies that have been put into place to ensure that no one entity or organization has undue influence on Reagan-Udall Foundation initiatives and projects.
Board of Directors
The board members are an extraordinary group of leaders with diverse talents and experience.
- Ellen V. Sigal, Ph.D., Board Chair
- Richard L. Schilsky, M.D., Vice Chairman
- Helen Darling, MA, Treasurer
- Kay Holcombe, MS, Secretary
- Mark McClellan, M.D., Ph.D., Chairman, IMEDS Committee
- Edward John Allera, J.D.
- Georges C. Benjamin, M.D.
- Allan Coukell, BScPharm
- Molly Fogarty
- Sally J. Greenberg, J.D.
- Adrian F. Hernandez, M.D.
- Jonathan Leff, MBA
- Garry Neil, M.D.
- Andrew C. von Eschenbach, M.D.
- Lynne Zydowsky, Ph.D.
- Stephen M. Hahn M.D., 24th Commissioner of Food and Drugs, U.S. Food and Drug Administration
- Francis Collins, M.D., Director, National Institutes of Health
- Amar Bhat, PhD, Interim Executive Director
- Ngozi Amaechi, Communications Associate
- Lea Ann Browning-McNee, MS, Director of Communication and Engagement
- Greg Daphnis, MPH, Scientific Program Manager
- Elizabeth Fain, Executive Assistant
- Carla Rodriguez-Watson, PhD, IMEDS Scientific Director
- Dave Woodbury, MBA, Director of Operations